Catalyst Pharmaceuticals, Inc. provided revenue guidance for full year 2022. The Company forecasts 2022 full year total revenues to be in the range of between $195 million and $205 million, representing a 38%-45% increase in total revenues as compared to 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.17 USD | +0.37% | +1.89% | -3.81% |
05-30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
05-30 | Catalyst Pharmaceuticals Gets FDA Approval for Dose Increase in LEMS Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.81% | 1.91B | |
-2.06% | 89.87B | |
-3.95% | 37.57B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B | |
-19.77% | 7.32B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2022